Adjusted EBITDA (non-GAAP) was $4.1 million for the fourth quarter of 2025, compared to a loss of $16.4 million for the fourth quarter of the prior year. Excluding revenue generated from the Genentech ...
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...
This new article publication from Acta Pharmaceutica Sinica B, discusses how the use of a radiation-based immunogenic vaccine combined with a macrophage “checkpoint inhibitor” can boost innate and ...
A new review by Dr. Ruyuan Wang and an international team of researchers explores the complex interactions between the innate and adaptive immune systems, shedding light on regulatory mechanisms in ...
Our immune system is divided into two main branches: innate and adaptive. Innate immune cells act as a first line of defense, quickly responding to invaders, while adaptive immune cells take a longer ...
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.5, with a high ...
Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans' innate immunity, according to research from UCL. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results